| IL-6 Biomarker | |
|---|---|
| Full Name | Interleukin-6 |
| Gene | IL6 |
| Protein Class | Cytokine (IL-6 family) |
| Primary Role | Pro-inflammatory cytokine |
| Detection Method | ELISA, Simoa, multiplex |
| Sample Type | CSF, Blood (serum/plasma) |
Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in immune regulation, inflammation, and neuronal function. It has emerged as an important biomarker for neuroinflammation in neurodegenerative diseases. Elevated IL-6 levels in cerebrospinal fluid (CSF) and blood are associated with disease progression and severity in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
IL-6 is a 184-amino acid glycoprotein (molecular weight ~26 kDa) encoded by the IL6 gene on chromosome 7p15.3. It signals through two receptor complexes:
| Function | Neuronal Relevance |
|---|---|
| Acute phase response | Neuroinflammation initiation |
| B cell differentiation | Adaptive immune activation |
| Hematopoiesis | Microglial development |
| Muscle regeneration | CNS repair mechanisms |
| Neuronal survival | Neuroprotective effects (acute) |
CSF IL-6 findings:
| Parameter | AD | Controls | P-value |
|---|---|---|---|
| CSF IL-6 (pg/mL) | 3.5-8.2 | 1.8-3.1 | <0.001 |
| Serum IL-6 (pg/mL) | 2.9-5.8 | 1.2-2.5 | <0.001 |
Mechanistic role:
CSF IL-6 findings:
Mechanistic role:
| Disease | CSF IL-6 | Clinical Correlation |
|---|---|---|
| Frontotemporal Dementia | Elevated | Disease severity |
| Huntington's Disease | Variable | Motor symptoms |
| Multiple Sclerosis | Elevated | Active inflammation |
| Creutzfeldt-Jakob Disease | Very high | Rapid progression |
Standard method with good sensitivity:
Ultra-sensitive digital immunoassay:
Simultaneous measurement of multiple cytokines:
| Application | Evidence Level |
|---|---|
| AD progression | Strong |
| PD severity | Moderate |
| ALS survival | Moderate |
| MCI→AD conversion | Moderate |
| Drug | Target | Status in NDs |
|---|---|---|
| Tocilizumab | IL-6R | Trials in AD, off-label use |
| Sarilumab | IL-6R | Preclinical |
| Siltuximab | IL-6 | Phase 1 trials |
| Batoclimab | IL-6R | Research stage |
For clinical use, IL-6 is combined with:
The study of Il 6 (Interleukin 6) In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.